| Document Date: 2012-02-10 21:17:35
Open Document File Size: 130,19 KBShare Result on Facebook
City Vancouver / CAMBRIDGE / / Company Hydra Biosciences Inc. / Hydra Biosciences Hydra Biosciences / Zalicus Inc. / Cubist Pharmaceuticals / Hydra Collaborate / / Currency USD / / Event Patent Filing / Funding / Business Partnership / Layoffs / FDA Phase / Reorganization / / IndustryTerm biopharmaceutical / / MedicalCondition immuno-inflammatory diseases / pain / diseases / inflammation / infectious disease / / Person Russell Herndon / Mark H.N. Corrigan / / Position leader in ion channel research and development / CEO / leader / Chief Executive Officer / / Product Zalicus / Z-160 / Z944 / / ProvinceOrState British Columbia / Massachusetts / / Technology drug development / / URL www.zalicus.com / / |
Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain CAMBRIDGE, Mass. – February 9, 2012 – Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and